论文部分内容阅读
近年来临床上积极研究的抗心律失常药物品种迅速增多.室性心律失常(VA)的减少或消除常作为试验终点.然部份VA患者虽无症状但心源性猝死(SCD)增加,因而,对于这些患者的临床试验终点应取预防心源性猝死为宜.一、VA患者群体心源性猝死是20～64岁美国人的主要死亡原因.Holter监测示:心源性猝死前约80%患者有室性快速心律失常,如室性心动过速(室速)和/或心室扑动,后转为致死性心室颤动,另20%患者心肌缺血急性发作导致缓慢心律失常或心脏停搏.临床和流行病调查表明,心源性猝死的二个主要易患因素为
In recent years, active research in clinical anti-arrhythmic drugs rapidly increased.Viral ventricular arrhythmia (VA) reduction or elimination often as the end of the trial.Although some patients with VA but no symptoms of sudden cardiac death (SCD) increase, therefore, For these patients the clinical trial endpoint should be taken to prevent sudden cardiac death is appropriate.First, sudden cardiac death in patients with VA is the main cause of death of Americans aged 20 to 64.Holter monitoring shows: about 80% Patients with ventricular tachyarrhythmia, such as ventricular tachycardia (VT) and / or ventricular flutter, later converted to lethal ventricular fibrillation, and the other 20% of patients with acute myocardial ischemia caused by slow arrhythmia or cardiac arrest Clinical and epidemiological surveys show that the two major predisposing factors for sudden cardiac death are